Bronchopulmonary dysplasia, Lancet, vol.367, pp.1421-1431, 2006. ,
Chronic oxygen dependency in infants born at less than 32 weeks' gestation: incidence and risk factors, Pediatrics, vol.108, p.26, 2001. ,
Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period, Pediatrics, vol.82, pp.527-532, 1988. ,
Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia, Birt Defects Res A Clin Mol Teratol, vol.100, pp.189-201, 2014. ,
Postnatal steroids: a dilemma for the neonatologist, Acta Paediatr Oslo Nor, vol.90, pp.116-118, 1992. ,
Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants, Pediatrics, vol.124, pp.673-679, 2009. ,
Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants, Intensive Care Med, vol.25, pp.717-721, 1999. ,
Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants, Cochrane Database Syst Rev, vol.5, p.1146, 2014. ,
Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants, Cochrane Database Syst Rev, vol.5, p.1145, 2014. ,
Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review, Neonatology, vol.98, pp.217-224, 2010. ,
Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review, Neonatology, vol.98, pp.289-296, 2010. ,
Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review, Neonatology, vol.98, pp.111-117, 2010. ,
Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial, Lancet Lond Engl, vol.387, pp.1827-1836, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01278609
Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants, N Engl J Med, vol.341, pp.1190-1196, 1999. ,
, Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants, Pediatrics, vol.109, pp.330-338, 2002.
Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Paediatr Child Health, vol.17, pp.573-574, 2012. ,
Changes in the Use of Postnatal Steroids for Bronchopulmonary Dysplasia in 3 Large Neonatal Networks, PEDIATRICS, vol.118, pp.1328-1335, 2006. ,
Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants, Arch Dis Child Fetal Neonatal Ed, vol.92, pp.30-33, 2007. ,
Rates of Bronchopulmonary Dysplasia in Very Preterm Neonates in Europe: Results from the MOSAIC Cohort, Neonatology, vol.99, pp.112-117, 2011. ,
Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in france in 2011: Results of the epipage-2 cohort study, JAMA Pediatr, 2015. ,
Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort, J Pediatr, vol.157, pp.733-739, 2010. ,
European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update, Neonatology, vol.97, pp.402-417, 2010. ,
Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants, Cochrane Database Syst Rev, p.1146, 2010. ,
European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2013 update, Neonatology, vol.103, pp.353-368, 2013. ,
Evidence based medicine: what it is and what it isn't, Clin Orthop, vol.455, pp.3-5, 1996. ,
Early CPAP versus surfactant in extremely preterm infants, N Engl J Med, vol.362, pp.1970-1979, 2010. ,
Prophylactic or early selective surfactant combined with nCPAP in very preterm infants, Pediatrics, vol.125, pp.1402-1409, 2010. ,
The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs, BMC Pediatr, vol.1, p.1, 2001. ,
Utilisation de la corticothérapie postnatale chez le nouveau-né prématuré dans la prévention et le traitement de la dysplasie bronchopulmonaire: état des lieux et conduite à tenir, Arch Pédiatrie, vol.17, pp.1480-1487, 2010. ,
Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia. Pediatrics, vol.126, pp.800-808, 2010. ,
Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams, Pediatrics, vol.111, pp.534-541, 2003. ,
Standards and Guidelines for Observational Studies: Quality is in the Eye of the Beholder, J Clin Epidemiol, 2015. ,
An Update on the Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk of Bronchopulmonary Dysplasia, J Pediatr, vol.165, pp.1258-1260, 2014. ,